



Press Release

Tuesday, January 18, 2011

Strides Arcolab Limited,
Strides House,
Bannerghatta Road,
Bangalore – 560076, India

BSE: 532531
NSE: STAR

STRIDES ARCOLAB ANNOUNCES USFDA APPROVAL FOR ADDITIONAL ADENOSINE INJECTION USP

- **Approval Momentum Continues**
- **Total Sterile Approvals To Date 34**

Strides Arcolab Limited (Strides) today announced that the USFDA has granted approval for an additional package size of Adenosine Injection, USP, 3 mg/ML packaged in 12 mg/ 4 mL single-dose vials.


The product will be launched upon expiry of applicable innovator patents.

September 2010 IMS data indicates that the US innovator market for Adenosine presentations approximated US\$ 94 million. Strides had, in 2010, received approval for Adenosine Injection - 60 mg per 20 mL and 90 mg per 30 mL vials.

The product will be launched under the partnership between Strides and Sagent Pharmaceuticals wherein Strides is developing and supplying more than 25 injectable products for the US market which is to be marketed by Sagent.

About Adenosine Injection

Adenosine is an endogenous nucleoside occurring in all cells of the body. Adenosine injection is a sterile solution for rapid bolus intravenous injection. Adenosine injection slows conduction time through the A-V node, can interrupt the reentry pathways through the A-V node, and can restore normal sinus rhythm in patients with paroxysmal supraventricular tachycardia (PSVT). Intravenous adenosine injection has been effectively administered in the presence of other cardioactive drugs without any change in the adverse reaction profile.



About Strides Arcolab Limited:

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.

The company has 14 manufacturing facilities across 6 countries with presence in more than 75 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore.

Additional information is available at the company's website at www.stridesarco.com.

For further information, please contact:

<u>Strides</u>	<u>PR Consultancy</u>
Mr. V.S. Iyer, Executive Director +91 80 66580111	Corporate Voice/Weber Shandwick
Mr. Kannan. N (Investors) +91 98450 54745	Mahesh Nair, +91 9880376648 maheshn@corvoshandwick.co.in
Melissa Arulappan (Media) +91 98450 22389	Hiba Kunil +91 98807 26372 hiba@corvoshandwick.co.in

